Ranolazine, a piperazine derivative, is an anti-anginal drug used to treat cardiac ischemia. In myocardial ischemia, it works by altering sodium-dependent calcium channels, so avoiding calcium overload, which results in heart ischemia. When taken in conjunction with other treatments such as beta-blockers, nitrates, calcium channel blockers, antiplatelet medication, lipid-lowering medicines, ACE inhibitors, and angiotensin receptor blockers, ranolazine is helpful for treating chronic angina. A new anti-ischemic drug called ranolazine inhibits reverse mode sodium-calcium exchange, which lowers diastolic calcium accumulation by suppressing late INa to prevent cellular sodium overload. By directly addressing myocardial ischemia, this technique can raise coronary blood flow and diastolic tone. The several analytical techniques that have been documented for the determination of ranolazine in synthetic mixtures are represented in this review article. Chromatographic techniques were reported, including GC, LC-MS, RP-HPLC, HPTLC, HPLC, and LC-MS/MS.
Ranolazine, HPTLC, HPLC, LC-MS
